查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466630

抗體藥物複合體市場：按作用機制、藥物、技術、適應症和最終用戶 - 2024-2030 年全球預測

Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體藥物複合體市場規模為56億美元，預計2024年將達到64.8億美元，2030年將達到159.6億美元，複合年成長率為16.12%。

抗體藥物複合體(ADC) 涉及結合單株抗體和細胞毒性藥物的治療分子的開發、製造和商業化。這些混合化合物選擇性地靶向並消除癌細胞，同時最大限度地減少對健康組織的毒性。與傳統化療相比，ADC 因其療效提高和副作用減少而廣泛應用於腫瘤學。全球癌症發生率的持續上升增加了對 ADC 等創新治療方法的需求。然而，ADC 的製造過程可能複雜且具有挑戰性，需要多個步驟和嚴格的品管措施來確保產品的同質性和穩定性。針對 ADC 技術在癌症以外的疾病（例如自體免疫疾病和感染疾病）的應用的研究也在進行中，預計將加速全球最終用途部門對 ADC 的使用。

主要市場統計
基準年[2023] 56億美元
預測年份 [2024] 64.8億美元
預測年份 [2030] 159.6億美元
複合年成長率（%） 16.12%

作用機轉：ErbB2 抗體 (HER2) 作為乳癌和胃癌的有效治療方法越來越受到青睞

CD30 抗體是一種針對 CD30 抗原的 ADC（抗體藥物複合體），該抗原在多種類型的癌症中過度表達，包括異生性大細胞淋巴瘤、何傑金氏淋巴瘤和其他 T 細胞淋巴瘤。這些 ADC 在臨床試驗中顯示出有希望的結果，並因其在向癌細胞輸送細胞毒性藥物同時保護健康組織方面的效率和特異性而被廣泛使用。 ErbB2 抗體是另一類針對人類表皮生長因子受體 2 (HER2) 的 ADC，HER2 在癌細胞增殖中扮演重要角色。 HER2 過度表現發生在多種惡性中，包括乳癌和胃癌。 ErbB2 標靶 ADC 可有效改善這些常規治療方法失敗的疾病患者的預後。

藥物：Enhertz 作為癌症領域標靶治療的有前景藥物的滲透

ADCETRIS（brentuximab vedotin）用於治療多種淋巴瘤亞型，包括異生性大細胞淋巴瘤（ALCL）、何傑金氏淋巴瘤（HL）和周邊T細胞淋巴瘤（PTCL）。其臨床成功歸因於其能夠使用一種名為單甲基auristatin E (MMAE)的強效細胞毒性藥物靶向表達CD30的癌細胞，該藥物此前限制了治療選擇，從而提高了患者的整體生存率。 Brenrep（belantamab mafodotin blmf）解決了治療復發性或難治性多發性骨髓瘤中未滿足的需求。它透過施用一種名為單甲基auristatin F (MMAF) 的強效微管破壞劑來靶向惡性漿細胞上的 B 細胞成熟抗原 (BCMA)。 Enhertu（fam-trastuzumab deruxtecan-nxki）是為治療轉移性 HER2 陽性乳癌而開發的，與曲妥珠單抗 emtansine (T-DM1) 等標準治療相比，無惡化無惡化生存期顯著增加。 Kadcyla（Ado-trastuzumab Emtansine）是一種治療 HER2 陽性轉移性乳癌患者的藥物。它用於先前接受過曲妥珠單抗和紫杉烷治療的患者。其獨特的作用機制是將一種稱為 DM1 的高效細胞毒性藥物標靶遞送至 HER2 過度表現的癌細胞。 Padoseb（enfortumab vedotin-ejfv）用於治療晚期尿路上皮癌，具有很高的未滿足的醫療需求。它選擇性地靶向在尿路上皮癌中高表達的黏附分子Nectin-4，並直接向癌細胞施用強效細胞毒劑MMAE。 Trodelvy (sacituzumab govitecan-hziy) 解決了三陰性乳癌 (TNBC) 治療中未滿足的需求，其特點是治療選擇有限且預後不良。

技術：優先考慮無連結器技術，以簡化製造流程並提高 ADC 穩定性

可裂解接頭技術旨在透過特定的酶促或化學裂解在癌細胞內選擇性釋放細胞毒性藥物。這種方法提高了治療效果，同時最大限度地減少了脫靶毒性。無連接 ADC 將細胞毒性藥物直接附著到抗體上，無需使用額外的連接分子。這簡化了製造流程並提高了ADC產品的穩定性和同質性。不可溶性接頭堅固且穩定，旨在在被目標癌細胞攝取後釋放細胞毒性有效負載，同時在血流中保持完整。不可分解連接體的優點是穩定性高，可降低藥物過早釋放和脫靶毒性的風險。可切割接頭在癌細胞內選擇性活化並抑制脫靶毒性，但與其他技術相比可能會遭受系統性不穩定的影響。無連結 ADC 可以簡化製造流程並提高產品同質性，但可能用途較差，因為它們需要直接綴合。儘管不可可溶性連接體提高了血流內的穩定性，但有效的藥物釋放高度依賴抗體的有效內化。

適應症：快速使用ADC有效治療乳癌

ADC 是治療淋巴瘤、白血病和多發性骨髓瘤等血癌的可靠治療方法，因為它們可以針對惡性細胞上表現的腫瘤特異性抗原，同時不傷害正常造血細胞。 ADC 由於能夠針對過度表達的受體（包括 HER2），因此在乳癌治療中受到關注。 ADC 廣泛用於治療白血病，這是一種以快速產生異常白血球為特徵的血癌。淋巴瘤是淋巴系統的癌症，分為何何傑金氏病型和非何何傑金氏病型。針對惡性淋巴細胞上特異性抗原的 ADC 已有效治療這些癌症。多發性骨髓瘤是一種影響骨髓的漿細胞癌，靶向 B 細胞成熟抗原 (BCMA) 的 ADC 在治療這種惡性方面已顯示出前景。 ADC 也顯示出治療尿路上皮癌和膀胱癌的潛力，因為它們能夠針對這些惡性中過度表現的特定蛋白質。

最終用戶：學術研究機構新開發的ADC新用途

在學術研究機構中，ADC 對於提高我們對癌症生物學和治療機制的理解至關重要。研究人員正在使用 ADC 來研究癌細胞與腫瘤微環境之間的複雜相互作用。生物製藥和生物技術公司處於 ADC 開發和商業化的前沿，大力投資研發工作，以發現新的抗體藥物複合體物標靶和有效負載，同時改進藥物連接器技術。醫院在透​​過臨床試驗檢驗ADC 的有效性方面也發揮著至關重要的作用。癌症中心是跨學科專業知識和最尖端科技的中心，促進研究成果轉化為臨床實踐。癌症中心創造了一個腫瘤學家、病理學家、藥理學家和放射學家合作的環境，透過精準醫療改善病患照護。

區域洞察

由於腫瘤學的進步和對標靶治療的需求，抗體藥物複合體（ADC）市場正在美洲發展。強大的研究基礎設施和有利的創新環境正在推動 ADC 在美洲的發展。在歐盟 (EU)，ADC 的中央行銷核准由歐洲藥品管理局 (EMA) 進行。近年來，歐盟開展了多項開發新型 ADC 療法的策略合作。由於醫療支出的增加和標靶治療意識的增強，中東和非洲地區的潛力開拓。不斷上升的研發成本和癌症的流行正在推動亞太地區對 ADC 的需求。此外，在 ADC 製造中引入和利用先進技術預計將增加其在全球最終用途領域的採用。

FPNV定位矩陣

FPNV定位矩陣對於評估抗體藥物複合體市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體藥物複合體市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.抗體藥物複合體市場規模及預測如何？

2.抗體藥物複合體市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.抗體藥物複合體市場的技術趨勢和法規結構是什麼？

4.抗體藥物複合體市場主要供應商的市場佔有率是多少？

5. 進入抗體藥物複合體市場的合適形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率增加
      • 臨床試驗活動的成長和強大的產品平臺
      • 政府對癌症研究的支持與努力
    • 抑制因素
      • 高 ADC 製造成本和產品召回
    • 機會
      • 加大生物製藥研發投入並推出新型ADC
      • 採用先進技術進行ADC開發
    • 任務
      • ADC 製造複雜性
  • 市場區隔分析
    • 作用機轉：提高ErbB2抗體（HER2）有效治療乳癌和胃癌的優越性
    • 藥物：Enhertz 作為一種有前景的腫瘤標靶治療藥物的滲透
    • 技術：優先採用無連結器技術來簡化製造流程並提高 ADC 穩定性
    • 適應症：快速使用ADC有效治療乳癌
    • 最終用戶：學術研究機構新開發的ADC新用途
  • 市場趨勢分析
    • 專注於確保新 ADC 藥物在美洲獲得核准
    • 改善亞太地區癌症和醫療基礎設施的負擔
    • 政府支持活動以改善歐洲、中東和非洲的癌症研究和治療
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章抗體藥物複合體市場：按作用機制

  • CD30抗體
  • ErbB2抗體

第7章抗體藥物複合體市場：依藥物分類

  • ADCETRIS
  • 布倫代表
  • 恩赫圖
  • 門頭
  • 帕多切夫
  • 特羅德維

第8章抗體藥物複合體市場：依技術分類

  • 可切割接頭
  • 無連結器
  • 不可切割的接頭

第9章抗體藥物複合體市場：依適應症分類

  • 血癌
  • 乳癌
  • 淋巴瘤
  • 多發性骨髓瘤
  • 尿路上皮癌和膀胱癌

第10章抗體藥物複合體市場：依最終用戶分類

  • 學術研究所
  • 生物製藥和生物技術公司
  • 醫院
  • 專門癌症中心

第11章美洲抗體藥物複合體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太抗體抗體藥物複合體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗體藥物複合體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • Lonza 加強抗體藥物複合體的商業供給能力
    • CHMP 建議歐盟核准ENHERTU 用於治療 HER2 突變的晚期非小細胞肺癌患者
    • Pyxis Oncology 完成對 Apexigen 的收購
    • 百濟神與 DualityBio 宣布合作推進固態腫瘤差異化抗體藥物複合體(ADC) 療法
    • 諾華支持的 Tagworks 籌集了 6,500 萬美元的 A 輪融資，以進一步推進 ADC、點擊發布技術
    • Lonza 收購 Synafix 以加強抗體藥物複合體產品
    • 索尼和安斯泰來簽署合作研究協議，探索新的腫瘤學 ADC 平台
    • BioNTech 與 DualityBio 建立全球戰略合作夥伴關係，加速固態腫瘤差異化抗體藥物複合體療法的開發
    • 輝瑞投資430億美元對抗癌症
    • 阿斯特捷利康與 KYM Biosciences 簽署 Claudin-18.2抗體藥物複合體CMG901授權合約
    • 美國FDA核准Trodelvy 用於治療先前接受過治療的 HR+/HER2- 轉移性乳癌患者

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-657F2A76F4DB

[195 Pages Report] The Antibody Drug Conjugate Market size was estimated at USD 5.60 billion in 2023 and expected to reach USD 6.48 billion in 2024, at a CAGR 16.12% to reach USD 15.96 billion by 2030.

The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 5.60 billion
Estimated Year [2024] USD 6.48 billion
Forecast Year [2030] USD 15.96 billion
CAGR (%) 16.12%

Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer

CD30 antibodies are a class of antibody drug conjugates (ADCs) that target the CD30 antigen, which is overexpressed in several types of cancers such as anaplastic large cell lymphoma, Hodgkin's lymphoma, and other T-cell lymphomas. These ADCs have exhibited promising results in clinical trials and have been widely used for their efficiency and specificity in delivering cytotoxic agents to cancer cells while sparing healthy tissues. ErbB2 antibodies are another class of ADCs that target the human epidermal growth factor receptor 2 (HER2), which plays a crucial role in the proliferation of cancer cells. Overexpression of HER2 occurs in various malignancies, including breast cancer and gastric cancer. ErbB2-targeting ADCs have been effective in improving outcomes for patients suffering from these diseases where traditional therapies have failed.

Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field

Adcetris (brentuximab vedotin) is employed for the treatment of various lymphoma subtypes, such as anaplastic large cell lymphoma (ALCL), Hodgkin's lymphoma (HL), and peripheral T-cell lymphomas (PTCL). Its clinical success is attributed to its ability to target CD30-expressing cancer cells with a potent cytotoxic agent known as monomethyl auristatin E (MMAE), leading to enhanced overall survival rates in patients with limited treatment options in the past. Blenrep (belantamab mafodotin-blmf) addresses an unmet need in treating relapsed or refractory multiple myeloma. It targets B-cell maturation antigen (BCMA) on malignant plasma cells by delivering a potent microtubule-disrupting agent called monomethyl auristatin F (MMAF). Enhertu (fam-trastuzumab deruxtecan-nxki) was developed for the treatment of metastatic HER2-positive breast cancer and has demonstrated significant advancement in progression-free survival as compared to standard therapies such as trastuzumab emtansine (T-DM1). Kadcyla (ado-trastuzumab emtansine) is a solution for patients with HER2-positive metastatic breast cancer. It is used in patients previously treated with trastuzumab and taxane therapy. Its unique mechanism of action involves the targeted delivery of a highly potent cytotoxic agent called DM1 to HER2-overexpressing tumor cells. Padcev (enfortumab vedotin-ejfv) is used to treat advanced urothelial cancer, representing a considerable unmet medical need. It selectively targets Nectin-4, an adhesion molecule highly expressed in urothelial cancers, and delivers the potent cytotoxic agent MMAE directly to tumor cells. Trodelvy (sacituzumab govitecan-hziy) addresses an unmet need in treating triple-negative breast cancer (TNBC), a subtype characterized by limited therapeutic options and poor prognosis.

Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs

The cleavable linker technology is designed to release the cytotoxic drug selectively within the tumor cells through specific enzymatic or chemical cleavage. This approach increases therapeutic efficacy while minimizing off-target toxicities. Linkerless ADCs employ direct conjugation of the cytotoxic drug to the antibody without using any additional linker molecules. This simplifies the manufacturing process and improves the stability and homogeneity of ADC products. Non-cleavable linkers are robust and stable, designed to remain intact within the bloodstream while releasing their cytotoxic payload upon internalization into targeted tumor cells. The advantage of non-cleavable linkers is their enhanced stability, reducing the risk of premature drug release and off-target toxicity. Cleavable linkers provide selective activation within tumor cells, limiting off-target toxicities; however, they may suffer from higher systemic instability than other technologies. Linkerless ADCs offer streamlined manufacturing processes and possible improvements in product homogeneity and may be less versatile due to direct conjugation requirements. Non-cleavable linkers offer increased stability within the bloodstream; however, they rely heavily on efficient antibody internalization for effective drug release.

Indication: Rapid usage of ADCs for efficient treatment of breast cancer

ADCs have emerged as a reliable therapy for blood cancers, including lymphoma, leukemia, and multiple myeloma, due to their ability to target tumor-specific antigens expressed on malignant cells while sparing normal hematopoietic cells. ADCs are gaining attention in breast cancer treatment due to their ability to target overexpressed receptors, including HER2. ADCs are widely used in treating leukemia, a blood cancer characterized by the rapid production of abnormal white blood cells. Lymphomas are cancers of the lymphatic system and include Hodgkin and non-Hodgkin subtypes. ADCs targeting specific antigens on malignant lymphocytes have effectively treated these cancers. Multiple myeloma is a type of cancer of plasma cells that affects bone marrow, and ADCs targeting B-cell maturation antigen (BCMA) show potential for treating this malignancy. ADCs also demonstrate potential in urothelial and bladder cancer treatment owing to their ability to target specific proteins overexpressed in these malignancies.

End User: Emerging use of ADCs by academic research institutes for novel developments

In academic research institutes, ADCs are essential in extending the understanding of cancer biology and therapeutic mechanisms. Researchers use ADCs to explore the complex interactions between tumor cells and the tumor microenvironment. Biopharmaceutical and biotechnology companies are at the forefront of ADC development and commercialization by investing heavily in R&D activities for discovering new antibody drug conjugate targets and payloads while improving drug-linker technologies. Hospitals also play a pivotal role in validating the effectiveness of ADCs through clinical trials. Specialized cancer centers serve as hubs for multidisciplinary expertise and state-of-the-art technologies that facilitate the translation of research findings into clinical practice. Specialized cancer centers foster an environment of collaboration between oncologists, pathologists, pharmacologists, and radiologists to enhance patient care through precision medicine.

Regional Insights

The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC therapy in recent years. The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugate Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugate Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugate Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Mechanism of Action
    • CD30 Antibodies
    • ErbB2 Antibodies
  • Drugs
    • Adcetris
    • Blenrep
    • Enhertu
    • Kadcyla
    • Padcev
    • Trodelvy
  • Technology
    • Cleavable Linker
    • Linkerless
    • Non-Cleavable Linker
  • Indication
    • Blood Cancer
    • Breast Cancer
    • Lymphoma
    • Multiple Myeloma
    • Urothelial Cancer & Bladder Cancer
  • End User
    • Academic Research Institutes
    • Biopharmaceutical & Biotechnology Companies
    • Hospitals
    • Specialized Cancer Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • Alaska
        • California
        • Florida
        • Illinois
        • Massachusetts
        • Michigan
        • Montana
        • Nevada
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Drug Conjugate Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugate Market?

3. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugate Market?

4. What is the market share of the leading vendors in the Antibody Drug Conjugate Market?

5. Which modes and strategic moves are suitable for entering the Antibody Drug Conjugate Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer worldwide
      • 5.1.1.2. Growth in clinical trial activities and robust product pipeline
      • 5.1.1.3. Government support and initiatives encouraging research on cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
      • 5.1.3.2. Adoption of advanced technologies for developing ADC
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of ADCs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
    • 5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
    • 5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
    • 5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
    • 5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
  • 5.3. Market Trend Analysis
    • 5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
    • 5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
    • 5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Antibody Drug Conjugate Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. CD30 Antibodies
  • 6.3. ErbB2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

  • 7.1. Introduction
  • 7.2. Adcetris
  • 7.3. Blenrep
  • 7.4. Enhertu
  • 7.5. Kadcyla
  • 7.6. Padcev
  • 7.7. Trodelvy

8. Antibody Drug Conjugate Market, by Technology

  • 8.1. Introduction
  • 8.2. Cleavable Linker
  • 8.3. Linkerless
  • 8.4. Non-Cleavable Linker

9. Antibody Drug Conjugate Market, by Indication

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Lymphoma
  • 9.5. Multiple Myeloma
  • 9.6. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Research Institutes
  • 10.3. Biopharmaceutical & Biotechnology Companies
  • 10.4. Hospitals
  • 10.5. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
    • 14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
    • 14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
    • 14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
    • 14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
    • 14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
    • 14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
    • 14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
    • 14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
    • 14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
    • 14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS ANTIBODY DRUG